Prognostic impact of p16 and p53 expression in oropharyngeal squamous cell carcinomas

Japanese Journal of Clinical Oncology

Volumn 44, Issue 3, 2014, Pages 232-240

  Shinohara, Shogo ^a   Kikuchi, Masahiro ^a   Tona, Risa ^a,b   Kanazawa, Yuji ^a   Kishimoto, Ippei ^a   Harada, Hiroyuki ^a   Imai, Yukihiro ^a   Usami, Yu ^a,c  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^c OSAKA UNIVERSITY DENTAL HOSPITAL   (Japan)

Author keywords

Human papilloma virus; Immunohistochemistry; Oropharyngeal carcinoma; p16; p53; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; FLUOROPYRIMIDINE; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; NEDAPLATIN; PLATINUM DERIVATIVE; PROTEIN P16; PROTEIN P53; CYCLIN DEPENDENT KINASE INHIBITOR 2A; P16 PROTEIN, HUMAN; TUMOR PROTEIN; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; HEALTH STATUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NECK DISSECTION; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PAPILLOMAVIRIDAE; PROTEIN EXPRESSION; RADIATION DOSE; RETROSPECTIVE STUDY; SMALL TONSILLAR CARCINOMA; SMOKING; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TONSIL CARCINOMA; TONSILLECTOMY; TREATMENT RESPONSE; CANCER STAGING; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; MORTALITY; OROPHARYNX CARCINOMA; OROPHARYNX TUMOR; P16; PAPILLOMA VIRUS; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; WART VIRUS;

HUMAN PAPILLOMA VIRUS; IMMUNOHISTOCHEMISTRY; OROPHARYNGEAL CARCINOMA; P16; P53; PROGNOSIS;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899491598     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt223     Document Type: Article

References (40)

1. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. New Engl J Med 2010;363:24-35.
2. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-9.
3. Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007;121:1813-20.
4. NCCN Clinical Practise Guideline in Oncology. Head and Neck Cancers. Version 1 2012. http://www.nccn.org.
5. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007;120:1731-8.
6. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J cancer 2007;121:2465-72.
7. Klussmann JP, Gultekin E, Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 2003;162:747-53.
8. Hoffmann M, Gorogh T, Gottschlich S, et al. Human papillomaviruses in head and neck cancer: 8 year-survival-analysis of 73 patients. Cancer Lett 2005;218:199-206.
9. Jo S, Juhasz A, Zhang K, et al. Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial. Anticancer Res 2009;29:1467-74.
10. Mellin H, Dahlgren L, Munck-Wikland E, et al. Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer 2002;102:152-8.
11. Strome SE, Savva A, Brissett AE, et al. Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. Clin Cancer Res 2002;8:1093-100.
12. Clayman GL, Stewart MG, Weber RS, et al. Human papillomavirus in laryngeal and hypopharyngeal carcinomas. Relationship to survival. Arch Otolaryngol Head Neck Surg 1994;120:743-8.
13. Kozomara R, Jovic N, Magic Z, et al. p53 mutations and human papillomavirus infection in oral squamous cell carcinomas: correlation with overall survival. J Craniomaxillofacial Surg 2005;33:342-8.
14. Field JK, Spandidos DA, Stell PM. Overexpression of p53 gene in head-and-neck cancer, linked with heavy smoking and drinking. Lancet 1992;339:502-3.
15. Field JK, Spandidos DA, Malliri A, et al. Elevated P53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. Br J Cancer 1991;64:573-7.
16. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
17. Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization Classification of Tumors. Pathology and Genetics Head and Neck Tumors. Lyon: IARC Press 2005.
18. Shinohara S, Kikuchi M, Tona R, et al. A comparison of three methods to detect human papilloma virus in oropharyngeal carcinoma: PCR-invader, Hybrid Capture and p16 immunohistochemistry staining. J Japan Soc Head Neck Surg 2013;23:163-8.
19. Schache AG, Liloglou T, Risk JM, et al. Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res 2011;17:6262-71.
20. Taylor D, Koch WM, Zahurak M, et al. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. Hum Pathol 1999;30:1221-5.
21. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008;26:3128-37.
22. Haraf DJ, Nodzenski E, Brachman D, et al. Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res 1996;2:755-62.
23. Smith EM, Ritchie JM, Summersgill KF, et al. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 2004;96:449-55.
24. Rolfe M, Beer-Romero P, Glass S, et al. Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP). Proc Natl Acad Sci USA 1995;92:3264-8.
25. Dyson N, Howley PM, Munger K, et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-7.
26. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-12.
27. Ritchie JM, Smith EM, Summersgill KF, et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 2003;104:336-44.
28. El-Mofty SK, Lu DW. Prevalence of high-risk human papillomavirus DNA in nonkeratinizing (cylindrical cell) carcinoma of the sinonasal tract: a distinct clinicopathologic and molecular disease entity. Am J Surg Pathol 2005;29:1367-72.
29. Sinha P, Lewis JS, Jr, Piccirillo JF, et al. Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancer 2012;118:3519-30.
30. Allen CT, Lewis JS, Jr, El-Mofty SK, et al. Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope 2010;120:1756-72.
31. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 2008;26:3138-46.
32. Sedaghat AR, Zhang Z, Begum S, et al. Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas. Laryngoscope 2009;119:1542-9.
33. van Houten VM, Snijders PJ, van den Brekel MW, et al. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 2001;93:232-5.
34. Wiest T, Schwarz E, Enders C, et al. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 2002;21:1510-7.
35. Bennett WP, Hollstein MC, He A, et al. Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene 1991;6:1779-84.
36. Nylander K, Nilsson P, Mehle C, et al. p53 mutations, protein expression and cell proliferation in squamous cell carcinomas of the head and neck. Br J Cancer 1995;71:826-30.
37. Broglie MA, Soltermann A, Rohrbach D, et al. Impact of p16, p53, smoking, and alcohol on survival in patients with oropharyngeal squamous cell carcinoma treated with primary intensity-modulated chemoradiation. Head Neck 2013;35:1698-706.
38. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
39. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
40. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23.